Payment overview · 2025
General Payments
$587.84
21 reported records · 9 companies
Healthcare provider profile · identity verified
Pratik A Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · MELBOURNE, FL · NPI 1114360831
Verified facts
What the public records show
CMS Open Payments records show Pratik A Patel, M.D. received $587.84 in general payments during 2025 across 21 reported records.
Boston Scientific Corporation accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Xifaxan.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $208.60 | 35.5% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $79.70 | 13.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.50 | 10.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.88 | 10.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.23 | 8.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $44.62 | 7.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.71 | 6.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $30.16 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.44 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.84 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $124.32 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $111.57 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $97.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 170 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
37 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 53 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 70 |
| Metformin Hcl | Metformin Hcl | 179 | 49 |
| Lisinopril | Lisinopril | 175 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 59 |
| Eliquis | Apixaban | 170 | 53 |
| Gabapentin | Gabapentin | 162 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 52 |
| Omeprazole | Omeprazole | 143 | 56 |
| Losartan Potassium | Losartan Potassium | 132 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 45 |
| Potassium Chloride | Potassium Chloride | 122 | 41 |
| Furosemide | Furosemide | 103 | 50 |
| Prednisone | Prednisone | 101 | 66 |
| Simvastatin | Simvastatin | 94 | 23 |
| Celecoxib | Celecoxib | 90 | 40 |
| Alprazolam | Alprazolam | 80 | 27 |
| Carvedilol | Carvedilol | 77 | 30 |
| Famotidine | Famotidine | 77 | 19 |
| Donepezil Hcl | Donepezil Hcl | 73 | 13 |
| Midodrine Hcl | Midodrine Hcl | 73 | 39 |
| Montelukast Sodium | Montelukast Sodium | 73 | 20 |
| Entresto | Sacubitril/Valsartan | 69 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 33 |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Methocarbamol | Methocarbamol | 62 | 49 |
| Alendronate Sodium | Alendronate Sodium | 60 | 19 |
| Tramadol Hcl | Tramadol Hcl | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 29 |
| Trazodone Hcl | Trazodone Hcl | 56 | 24 |
| Finasteride | Finasteride | 55 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 13 |
| Cefdinir | Cefdinir | 52 | 52 |
| Ezetimibe | Ezetimibe | 52 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 18 |
| Jardiance | Empagliflozin | 48 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Spironolactone | Spironolactone | 45 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 26 |
| Allopurinol | Allopurinol | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 23 |
| Ozempic | Semaglutide | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 23 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 31 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Glipizide | Glipizide | 38 | 12 |
| Linzess | Linaclotide | 37 | 12 |
| Xarelto | Rivaroxaban | 37 | 16 |
| Enulose | Lactulose | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 27 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | 13 |
| Valsartan | Valsartan | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.84 · 21 records | Boston Scientific Corporation | AMYVID, Cologuard Collection Kit, DUPIXENT, ELIQUIS, General - Therapies, KISUNLA, NURTEC ODT, OMVOH, Ozempic, TREMFYA, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error